COMPANY INFO
Nurix Therapeutics is a public biopharmaceutical company founded in 2009 by Arthur Weiss, John Kuriyan, and Michael Rape. It is headquartered in San Francisco, California, and has approximately 284 employees. The company focuses on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as novel treatments for cancer and immune disorders. Nurix leverages its proprietary DNA-encoded libraries and expertise in E3 ligases to develop targeted protein degradation drugs. Their official website is www.nurixtx.com.
Nurix Therapeutics Inc is a biopharmaceutical company founded in 2009, renowned for its cutting-edge work in the drug discovery industry. Headquartered in San Francisco, California, Nurix specializes in the discovery, development, and commercialization of small molecule therapies that modulate cellular protein levels, offering innovative treatments for cancer and immune disorders. The company harnesses its proprietary DNA-encoded library platform and expertise in E3 ligases to create targeted protein degradation drugs. With a staff of nearly 286 employees and a strong leadership team, Nurix Therapeutics Inc is at the forefront of next-generation therapeutics.
Nurix Therapeutics Inc has established a robust funding history, raising a total of $27.5 million across two funding rounds. The funding strategy emphasizes early partnerships with top venture capital firms and a focus on the expansion of their proprietary AI-driven drug development platform. Major funding milestones include an initial seed round supporting foundational technology development and a Series A round aimed at scaling research, development, and international operations. The company's fundraising efforts reflect a commitment to innovation and global expansion, solidifying Nurix Therapeutics Inc as a key player within the biotech venture capital ecosystem.
This Series A round was focused on strengthening Nurix Therapeutics Inc's technology stack, bolstering research and development capabilities, and enabling expansion of operations across Asia and North America.
The seed round provided essential capital for Nurix Therapeutics Inc's initial launch and the early development of their AI-driven enterprise solutions for drug discovery.
Accel is a prominent global venture capital firm that played a significant role as a lead investor in both the seed and Series A rounds for Nurix Therapeutics Inc. Their involvement offered strategic guidance and accelerated Nurix's R&D growth.
General Catalyst, another major venture capital investor, co-led the early funding rounds. Their investment has been instrumental in helping Nurix Therapeutics Inc advance its technology platform and scale its operations internationally.
Meraki Labs joined as a key investor, contributing expertise in computational biology and supporting Nurix Therapeutics Inc’s mission to innovate within the drug discovery landscape.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Nurix Therapeutics Inc funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.